Landscape of cancer biomarker testing in England following genomic services reconfiguration: insights from a nationwide pathologist survey.
Taniere, Phillipe Nicholson, Andrew G Gosney, John R Montero Fernandez, Maria Angeles Bury, Danielle Moore, David Allan Verghese, Eldo Soomro, Irshad Joseph, Leena Bhatt, Nidhi
Taniere, Phillipe
Nicholson, Andrew G
Gosney, John R
Montero Fernandez, Maria Angeles
Bury, Danielle
Moore, David Allan
Verghese, Eldo
Soomro, Irshad
Joseph, Leena
Bhatt, Nidhi
Citations
Altmetric:
Affiliation
Other Contributors
Publication date
2023-05-31
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Cancer diagnostics have been evolving rapidly. In England, the new National Health Service Genomic Medicine Service (GMS) provides centralised access to genomic testing via seven regional Genomic Laboratory Hubs. The PATHways survey aimed to capture pathologists' experience with current diagnostic pathways and opportunities for optimisation to ensure equitable and timely access to biomarker testing.
Methods: A nationwide survey was conducted with consultant pathologists from regional laboratories, via direct interviews based on a structured questionnaire. Descriptive analysis of responses was undertaken using quantitative and qualitative methods.
Results: Fifteen regional centres completed the survey covering a median population size of 2.5 (1.9-3.6) million (each for n=12). The median estimated turnaround time (calendar days) for standard molecular markers in melanoma, breast and lung cancers ranged from 2 to 3 days by immunohistochemistry (excluding NTRKfus in breast and lung cancers, and PD-L1 in melanoma) and 6-15 days by real-time-PCR (excluding KIT for melanoma), to 17.5-24.5 days by next-generation sequencing (excluding PIK3CA for breast cancer). Tests were mainly initiated by pathologists and oncologists. All respondents discussed the results at multidisciplinary team (MDT) meetings. The GMS roll-out was perceived to have high impact on services by 53% of respondents, citing logistical and technical issues. Enhanced education on new pathways, tissue requirements, report interpretation, providing patient information and best practice sharing was suggested for pathologists and other MDT members.
Conclusion: Our survey highlighted the role of regional pathology within the evolving diagnostic landscape in England. Notable recommendations included improved communication and education, active stakeholder engagement, and tackling informatics barriers.
Citation
Taniere P, Nicholson AG, Gosney JR, Montero Fernandez MA, Bury D, Moore DA, Verghese E, Soomro I, Joseph L, Bhatt N, Viola P, Bains R, Lanctot AG, Ryan J. Landscape of cancer biomarker testing in England following genomic services reconfiguration: insights from a nationwide pathologist survey. J Clin Pathol. 2024 Jun 19;77(7):486-494. doi: 10.1136/jcp-2023-208890.
Type
Article